LINKÖPING, Sweden, Dec. 6, 2024 /PRNewswire/ -- SyntheticMR, leader in quantitative imaging software, is pleased to announce that its SyMRI 15 solution has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) on diagnostic image replacement of conventional images.

SyMRI 15 offers an innovative approach to MRI, transforming traditional imaging methodologies with its advanced synthetic imaging technology. Clinically validated through extensive multi-center studies across leading institutions in the United States, SyMRI 15 has proven its capability to enhance imaging workflows by replacing conventional 3D imaging techniques in addition to its unique ability to provide tissue quantification. This technology offers significant gains in both efficiency and throughput while maintaining the highest standards of diagnostic accuracy.

CONTACT:

For additional information, please contact Vedran Beglerbegovic, acting CEO, SyntheticMR AB, +46 79 077 27 20 vedran.beglerbegovic@syntheticmr.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/syntheticmr-ab/r/syntheticmr-receives-fda-510-k--clearance-for-symri-15,c4078158

The following files are available for download:

https://mb.cision.com/Main/11663/4078158/3158232.pdf

Release

Cision View original content:https://www.prnewswire.com/news-releases/syntheticmr-receives-fda-510k-clearance-for-symri-15-302325245.html

SOURCE SyntheticMR AB

Copyright 2024 PR Newswire

Syntheticmr Ab (publ) (LSE:0G79)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Syntheticmr Ab (publ) 차트를 더 보려면 여기를 클릭.
Syntheticmr Ab (publ) (LSE:0G79)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Syntheticmr Ab (publ) 차트를 더 보려면 여기를 클릭.